|
|
|
|
| LEADER |
06447nmm a2200373 u 4500 |
| 001 |
EB000667047 |
| 003 |
EBX01000000000000000520129 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9783642595929
|
| 100 |
1 |
|
|a Büchner, T.
|e [editor]
|
| 245 |
0 |
0 |
|a Transplantation in Hematology and Oncology
|h Elektronische Ressource
|c edited by T. Büchner, H. Jürgens, W.E. Berdel, J.van de Loo, J. Ritter, J. Kienast, J. Vormoor
|
| 246 |
3 |
1 |
|a With contributions by numerous experts
|
| 250 |
|
|
|a 1st ed. 2000
|
| 260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 2000, 2000
|
| 300 |
|
|
|a XII, 342 p
|b online resource
|
| 505 |
0 |
|
|a Immunomagnetic Purging of Marrow and Peripheral Blood Progenitors for Autografting in Patients with Lymphoproliferative Disorders — Selection Efficacy and Engraftment -- Establishment of an NOD/SCID Mouse Model for Ewing Tumors: A Potential Preclinical Model to Test Novel Purging Strategies -- Molecular Genetic Detection of Minimal Metastatic and Residual Disease in Ewing’s Tumors -- Molecular Monitoring of Treatment Efficacy after Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia -- Detection of Residual Tumor Cells by RT-PCR for Tyrosine Hydroxylase mRNA -- Autologous Transplantation in Leukemias, Lymphomas, and Solid Tumors -- Autograft Followed by Allograft Without Myeloablative Conditioning Regimen: A New Approach for Resistant Hematologic Neoplasia and Breast Cancer -- Possible Prognostic Benefit from ABMT in First Remission Adult Acute Lymphoblastic Leukemia --
|
| 505 |
0 |
|
|a Updated Results of an Age-Adapted Consolidation Strategy with ABMT ( 50 Years) in Adult Acute Myeloid Leukemia -- Mobilization of Peripheral Blood Stem Cells after Intensive Induction and Consolidation Therapy in Adult Patients with De Novo Acute Myeloid Leukemia -- Autologous Stem Cell Transplantation in Acute Promyelocytic Leukemia Patients Achieving a Second Complete Remission -- Autologous Hematopoietic Cell Transplantation for Lymphoid Malignancies -- Dexa-BEAM with High-Dose Cytarabine and Autologous Bone Marrow Transplantation are Highly Effective in Heavily Pretreated Poor-Prognosis Lymphoma Patients -- Delayed Granulocyte Recovery and Suppressed Growth of Grafted CFU-GM If Allogeneic Marrow Cells are Transplanted 48 h After the Completion of High-Dose Busulfan and Cyclophosphamide (BuCy2) Therapy -- High-Dose Chemotherapy for Primary Metastatic or Relapsed Ewing Tumours: Outcome of 120 (EI) CESS Patients --
|
| 505 |
0 |
|
|a Nonmyeloablative Allogeneic Stem Cell Transplantation: Towards Improving Efficacy of Immunotherapy Instead of Myeloablative Chemoradiotherapy -- Autologous Peripheral Blood Stem Cell Transplantation in Childhood Metastatic Osteosarcoma -- Mycophenolate Mofetil for the Treatment of Acute and Chronic GVHD in Bone Marrow Transplant Patients -- Peripheral Blood and Bone Marrow Derived Dendritic Cells in Acute Myelogenous Leukemia -- Minimal Residual Disease: Detection and Treatment -- Biologic Effects of TBI -- Autologous Stem Cell Transplantation and Cell Therapy for Acute Leukemia -- Positive Selection of Hematopoietic Progenitor Cells for Autologous and Allogeneic Transplantation in Pediatric Patients with Solid Tumors and Leukemia -- Simultaneous Double-Purging of Breast Cancer Cells from Leukapheresis Products by Imunomagnetic CD34+ Cell Enrichment and Tumor Cell Depletion --
|
| 505 |
0 |
|
|a Transplantation: State of the Art -- Hematopoietic Cell Transplantation: The First 50 Years and a Glimpse of the Future -- Current Status of Blood and Marrow Transplantation -- Stem Cells and Growth Factors -- Normal and Leukemic Human Stem Cells -- Thrombopoietic Growth Factors — Managing Thrombocytopenia -- Erythropoietin Use in Therapy of Anemia Associated with Bone Marrow Transplantation in Children -- Autotransplantations of Peripheral Blood Progenitor Cells, Collected After Mobilization by Single-Dose Betaleukin (rh-IL-1b) -- Stem Cells: Donors and Sources -- Allogeneic Cord Blood Hematopoietic Stem Cell Transplants in Malignancies -- Future Source of Allogeneic Stem Cells: Bone Marrow or Peripheral Blood? -- Marrow Unrelated Donor Transplantation: European Experience -- Immune Effects and Cellular Immune Therapy -- New Strategies for Hematopoietic Stem Cell Transplantation --
|
| 505 |
0 |
|
|a Autologous Peripheral Blood Stem Cell Transplantation in Childhood Metastatic Osteosarcoma -- Approaches to Gene Therapy -- Retroviral Transfer and Expression of Drug Resistance Genes in Hematopoietic Cells -- Gene Therapy with Cord Blood Hematopoietic Stem Cells for Adenosine Deaminase Deficiency: An Update -- Adenovirus Mediated P53 (Adp53) Gene Transfer -- Pharmacological Gene Therapy for Experimental Brain Tumors -- Transgenic Expression of IL-2 in Peripheral Neuroectodermal Malignancies of Childhood: In Vitro and In Vivo Effects on Lymphocyte Activation and Tumor Lysis -- Suicide Gene Transduced T-Cells for the Regulation of the Graft-Versus-Leukemia Effect -- Defining Current Strategies for Future Human Trials in Gene Therapy
|
| 653 |
|
|
|a Hematology
|
| 653 |
|
|
|a Hematology
|
| 653 |
|
|
|a Oncology
|
| 653 |
|
|
|a Oncology
|
| 700 |
1 |
|
|a Jürgens, H.
|e [editor]
|
| 700 |
1 |
|
|a Berdel, W.E.
|e [editor]
|
| 700 |
1 |
|
|a Loo, J.van de
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-59592-9?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.15
|
| 520 |
|
|
|a Some three decades after bone marrow transplantation was introduced in the field of hematology and oncology, transplantation today continues to rapidly grow and expand into a variety of new modalities. Peripheral blood has been established as an effective source of autologous progenitor cells. Furthermore, the graft-versus-leukemia effect has resulted in novel strategies of adoptive immunotherapy for cancer. Finally, approaches to gene transfer and therapy can utilize transplantation methodologies and augment their effects. The present volume provides first-hand reports from leading groups covering approaches to stem cells, normal and leukemic; stem cell sources and donors; cellular immune therapy; minimal residual disease, monitoring and treatment; clinical autologous transplantation; and gene therapy, as well as the history and the state of the art of transplantation in hematology and oncology
|